Hormonal abnormalities of the reproductive axis have been described in obesity. In men, extreme obesity is associated with low serum testosterone (T) and high estrogen [estrone and estradiol (E 2 )] levels. As changes in the sex steroid milieu may profoundly affect the carbohydrate heterogeneity and thus some of the biological and physicochemical properties of the LH molecule, we analyzed the relative distribution of LH isoforms circulating under baseline conditions (endogenous GnRH drive) as well as the forms discharged by exogenous GnRH stimulation from putative acutely releasable and reserve pituitary pools in overweight men. Secondarily, we determined the impact of the changes in LH terminal glycosylation on the in vitro bioactivity and endogenous half-life of the gonadotropin. Seven obese subjects with body mass indexes ranging from 35.7-45.5 kg/m 2 and seven normal men with body mass indexes from 22.5-24.2 kg/m 2 underwent blood sampling at 10-min intervals for a total of 10 h before and after the iv administration of 10 and 90 g GnRH. Basally released and exogenous GnRH-stimulated serum LH isoforms were separated by preparative chromatofocusing and identified by RIA of eluent fractions. Serum pools of successive samples collected across 2-h intervals (five serum pools per subject) containing LH released under baseline and exogenous GnRH-stimulated conditions were tested for bioactivity employing a homologous in vitro bioassay. Mean serum T and E 2 levels were significantly lower and higher, respectively, in the obese men than in the control group [serum T, 13.5 Ϯ 2.4 vs.
subjects and normal controls (13.3 Ϯ 1.3 and 12.2 Ϯ 1.2 IU/L). Although multiple parameter deconvolution of the exogenous GnRH-induced LH pulses revealed that the magnitude of the pituitary response in terms of secretory burst mass, secretory amplitude, and half-duration of the LH pulses was similar in obese and control subjects, the apparent endogenous half-life of LH was significantly (P Ͻ 0.05) shorter in the obese group (98 Ϯ 11 min) than in the normal controls (132 Ϯ 10 min). Under all conditions studied, the relative abundance of basic isoforms (those with pH Ն7.0) was significantly (P Ͻ 0.05) increased in the obese subjects compared with the controls (percentages of LH immunoactivity recovered at pH Ն7.0: obese subjects, 34 -57%; normal controls, 22-46%). The biological to immunological ratio of LH released in baseline and low dose (10 g) GnRH-stimulated conditions were similar in obese subjects and normal controls, whereas LH released by obese subjects in response to the high (90 g) GnRH dose exhibited significantly lower ratios than those detected in normal individuals (0.62 Ϯ 0.07 and 0.45 Ϯ 0.09 vs. 1.01 Ϯ 0.10 and 0.81 Ϯ 0.09 for LH released within 10 -120 min and 130 -240 min after GnRH administration in obese and controls, respectively; P Ͻ 0.05). Collectively, these results indicate that the altered sex steroid hormone milieu characteristic of extreme obesity provokes a selective increase in the release of less acidic LH isoforms, which may potentially modify the intensity and duration of the blood LH signal delivered to the gonad. Altered glycosylation of LH may therefore represent an additional mechanism modulating the hypogonadal state prevailing in morbid obesity. (J Clin Endocrinol Metab 85: [4603] [4604] [4605] [4606] [4607] [4608] [4609] [4610] 2000) S EVERAL STUDIES have demonstrated that plasma total testosterone (T) concentrations are decreased in obese men compared with those found in nonobese men of similar age (1) (2) (3) (4) (5) . Moreover, there is decreased binding capacity of the sex hormone-binding globulin (SHBG) in obesity (2, 4 -6) . Accordingly, plasma free T concentrations in these subjects are less decreased than total T levels (3, 5) ; in fact, some studies report normal free T levels (1, 7) . These changes are inversely correlated with indexes of body weight, representing a continuum across varying degrees of obesity (3) . Weight loss can reverse these changes (7) . Likewise, elevated estrone and estradiol (E 2 ) concentrations have been documented in some obese men (4, 5, 7) .
In obese men, basal gonadotropin levels have been reported as being either within (1, 2) or below the normal limits (5, 8) . Vermeulen et al. (5) demonstrated that integrated serum LH concentrations are significantly lower in extremely obese individuals and that mean LH pulse amplitude as well as the mean sum of all diurnal LH pulse amplitudes are also decreased.
The mechanism(s) responsible for the changes in hormonal concentrations in obese men have not been clarified, although relative hyperinsulinism promotes a reduction in SHBG (4) . Whether the relative hypoandrogenism has a primary testicular or a hypothalamo-pituitary origin remains unknown. However, it has been reported that the response of Leydig cells to hCG stimulation is normal in obese men, suggesting that the primary cause of the decreased T concentrations does not reside within the testes (1, 9) . On the other hand, the associated hyperestrogenemia may influence gonadotropin regulation (5) .
Carbohydrates in LH and other glycoprotein hormones play a major role in structure and function. Oligosaccharides influence not only intracellular folding of the subunits and secretion of the glycoprotein heterodimer, but also its circulatory survival and capacity to evoke signal transduction at the receptor level (10 -13) . Several studies indicate that glycosylation of anterior pituitary glycoprotein hormones is regulated by hypothalamic inputs and/or by end products from the target glands under the control of these trophic hormones (14 -18) . The cellular mechanisms by which relevant feedback end products control glycosylation are known in part. For example, in situ hybridization studies have shown that the messenger ribonucleic acid levels of several glycosyltransferases (such as ␣-2,6-sialyltransferase, ␤-1,4-galactosyltransferase and ␣-mannosidase II) are significantly increased in thyrotrophs derived from hypothyroid mice (16, 17) . In the case of gonadotropins, Dharmesh and Baenziger (18) observed that the activity of both pituitary N-acetylgalactosamine transferase and sulfotransferase increased several-fold after ovariectomy, thereby favoring the production of more LH oligosaccharides terminating with sulfateGalNAc residues. Estrogen administration returned the activities of these transferases to basal levels (18) .
Considering the influence of sex steroids on the carbohydrate structure of both gonadotropins, we attempted to define the impact of the changes in the androgen to estrogen ratio in male obese subjects on the glycoprotein isoform distribution and in vitro biological activity of the LH signal synthesized and secreted by the anterior pituitary gland. For this purpose, we investigated the charge distribution (which in glycoprotein hormones is primarily dependent on the presence of terminal sulfate and/or sialic acid residues) and in vitro biological to immunological relationships of the LH isoforms released during baseline and GnRH-stimulated conditions in extremely obese compared with normal weight individuals. We assumed that consecutive administration of a low (10 g) and a high (90 g) GnRH dose would facilitate the identification of the various types of LH isoforms discharged from an intracellular, biologically enriched, LH releasable pool (19 -21) as well as forms of this gonadotropin that were newly synthesized in that particular endocrine milieu. The qualitative changes represented within the LH pulses released before and after GnRH administration from the anterior pituitary glands of obese and normal individuals were then correlated with the corresponding LH in vitro biological to immunological ratio (B/I ratio) as well as with LH secretory activity and half-lives, as resolved by multiparameter deconvolution analysis.
Subjects and Methods
Seven obese men, aged 24 -32 2 )] agreed to participate in the study. Approval from the human ethics committee of the institute and informed written consent from the volunteers were obtained. All subjects were in good general health; physical examination, including testicular size, was normal, as were the results of routine laboratory test of liver, kidney, and thyroid. All obese volunteers were single and manifested only decreased libido, but not impotence; none of the subjects in this group had received any dietary treatment or anorexigenic drugs during the previous 6 months. Volunteers were admitted to the metabolic research ward of the institute at 0730 h, and an indwelling heparinized iv catheter was placed in an antecubital vein. Starting at 0800 h, blood samples were obtained every 10 min for 10 h; at the beginning of the third hour, subjects received a rapid iv bolus of 10 g GnRH (Serono de Mexico, Mexico D.F., Mexico) and, 4 h later, a second GnRH bolus containing 90 g of the decapeptide. Subjects were recumbent during the study and consumed light meals at 0900 and 1400 h. Blood samples were allowed to clot at room temperature for 30 min, then were centrifuged at 1000 ϫ g. Sera were separated into three aliquots and stored frozen at Ϫ20 C until assay.
LH, FSH, T, and E 2 immunoassays
The RIA of LH was performed employing 125 I-labeled LH-I3 as the tracer (SA, 70 -90 Ci/g protein), the reference LH preparation LER-907 as the standard, and the antihuman LH-2, at a final dilution of 1:800,000, as the antiserum (22) . The sensitivity of the assay was 0.7 IU/L [1 mg LER-907 ϭ 277 IU of the Second International Reference Preparation of human menopausal gonadotropins (2nd IRP-HMG)]. Each subject's set of samples was processed in duplicate for LH determinations in a single RIA run. The intra-and interassay coefficients of variation were determined using multiple replicates (n ϭ 3/dose) of a serum pool collected from postmenopausal women, assayed at dose levels that displaced [
125 I]LH from the antibody at 15-23%, 45-59%, and 75-84% total binding; these coefficients ranged from 4.1-6.2% and 6.1-11.3%, respectively. All LH RIA reagents were provided by the NIDDK (Bethesda, MD) through Dr. A. F. Parlow from the National Hormone and Pituitary Program (Torrance, CA). Serum FSH was measured in the first and third baseline samples by an enzyme-linked immunoassay method (23) , employing a FSH standard preparation provided by the WHO Collaborating Center for Research and Reference Services in the Immunoassay of Hormones in Human Reproduction (London, UK) and calibrated against the International Reference Preparation 78/549; the sensitivity of the assay was 0.5 IU/L as expressed in terms of the 2nd IRP-HMG, and the intra-and interassay coefficients of variation at the ED 50 level were less than 7% and less than 13% respectively. Results of the LH and FSH immunoassays are expressed in international units according to the 2nd IRP-HMG. Reference ranges for the LH and FSH assays were 5-15 and 3-12 IU/L, respectively. Serum T and E 2 concentrations were determined in each sample collected during the baseline period by RIA after solvent extraction (recoveries Ͼ90% for both sex steroids) using antisera provided by the WHO Matched Reagent Program (Geneva, Switzerland) as previously described (24, 25) . Reference ranges for the T and E 2 assays were 15-30 and 0.036 -0.165 nmol/L, respectively. Intra-and interassay coefficients of variation for both assays (at 45-55% total binding) were less than 5% and less than 8%, respectively.
Chromatofocusing of serum samples
Serum samples from all subjects were subjected to concentration by dialysis and freeze-dried. LH isoforms were then separated on the basis of charge as previously described (22) . Briefly, for each individual series, samples corresponding to the (2-h) baseline period and to the low and high GnRH-stimulated study periods (4 h each) were separately pooled (three serum pools per subject; pools 1, 2-3, and 4 -5 in Fig. 1 ), transferred to dialysis membrane tubing (mol wt cut-off, 12,000 -14,000; Spectrum Medical Industries, Los Angeles, CA), dialyzed at 4 C for 24 h against deionized water and thereafter against 0.01 mol/L ammonium carbonate (pH 7.5), and freeze-dried. Lyophilates were redissolved to 1/10th the original volume in Pharmalyte (pH 8 -10.5)-HCl (Pharmacia Biotech, Piscataway, NJ; 1:45 dilution in deonized water, pH 7.0), and the suspension was then applied to the top of a 20 ϫ 1-cm column of polybuffer exchange resin (PBE-118, Pharmacia Biotech), previously equilibrated for 18 -24 h with 25 mmol/L triethylamine-HCl (pH 11.0) and chromatofocused at 4 C. Eluate fractions (2-mL each) were collected at a flow rate of 1 mL/4 min. The pH of each fraction was then measured, and when a limiting pH of 7.0 had been reached, the eluent buffer (Pharmalyte-HCl) was changed by Polybuffer-74 (Pharmacia Biotech) diluted 1:8 in deonized water (pH 4.0) to elute proteins bound at pH 7.0 -4.0. Proteins bound at the lower limiting pH (pH Ͻ4.0; salt peak) were finally recovered by the addition of 1.0 mol/L NaCl to the chromatofocusing column. Sets of fractions corresponding to eight 0.99 pH units were separately pooled, concentrated by dialysis and freeze-drying as described above, and stored frozen at Ϫ20 C until determination of its LH content by RIA. Each specimen was redissolved in phosphate (0.05 mol/L)-buffered physiological (0.15 mol/L) saline (pH 7.4), such that the majority of the dose levels fell on the linear portion of the LH RIA standard curve (Fig. 2) . To avoid interassay variations, all pooled fractions from the chromatofocusing separations were assayed in triplicate incubations in a single assay run.
In vitro bioassay of human LH
For each individual series of samples, those corresponding to the complete (2-h) baseline period and to the low and high GnRH-stimulated study periods were separately pooled, as shown in Fig. 1 (five serum pools per subject; pools 1-5 in Fig. 1 ), and assayed for cAMP production and immunoactive LH content. The capacity of each pool to provoke cAMP production was tested by a homologous in vitro bioassay, which employs the human embryonic kidney-derived 293 cell line transfected with the human LH receptor complementary DNA (provided by Dr. Aaron J. W. Hsueh, Stanford University, Stanford CA). The origin, handling, ligand specificity, and biochemical properties of the fulllength recombinant human LH receptor expressed by this cell line have been described previously (26) . Cells were cultured in DMEM (Life Technologies, Inc., Gaithersburg, MD), pH 7.3, supplemented with 2.5% FCS, 2 mmol/L l-glutamine, 100 mg/mL geneticin (Life Technologies, Inc.), 50 U/mL penicillin, and 100 g/mL streptomycin (Sigma, St. Louis, MO) and grown in 162-cm 2 flasks (Costar, Cambridge, MA). Confluent cells were scraped and plated in 24-well culture plates for 24 h at 37 C in 5% CO 2 . Cells (5 ϫ 10 4 cells/culture dish) were then washed and exposed to increasing doses (12.5-50 L) of each serum pool or LER-907 in the presence of 0.125 mmol/L 1-methyl-3-isobutylxanthine (Sigma) dissolved in 450 L supplemented DMEM for 24 h at 37 C. Samples (unknowns and standards) were diluted with serum from women treated with oral contraceptives that contained LH immuno-and bioactivities not distinguishable from the zero dose, such that the final concentration of human serum in each sample did not exceed 10% (50 L/culture well). After incubation, the media and cells were boiled at 90 C for 3 min and stored frozen at Ϫ20 C. The sensitivity of the assay was 0.075 mIU LER-907/tube. All pools from a single subject were bioassayed in triplicate incubations in a single assay run. The inter-and intraassay coefficients of variation at the ED 50 dose level were less than 18% and less than 10%, respectively. Aliquots (12.5-100 L) of samples from each serum pool series bioassayed were additionally analyzed for immunoreactive LH content as described above.
cAMP RIA
Total (intra-plus extracellular) cAMP levels were determined by RIA after acetylation of the samples and cAMP standards. The RIA of cAMP was performed as previously described (27) , employing 2-O-monosuccinyl cAMP tyrosylmethyl ester (Sigma) iodinated by the chloramine-T method and the CV-27 cAMP antiserum (NIDDK) at a final dilution of 1:50,000. After incubation at 4 C for 24 h, antibody-bound and free cAMP were separated by ethanol precipitation followed by centrifugation at 1,200 ϫ g at 4 C. The sensitivity of the assay was 4 fmol/tube and the inter-and intraassay coefficients of variation ranged from 8 -12% and from 4 -6%, respectively.
The relative in vitro biological activity of LH was calculated by interpolation. Data are expressed as the mean B/I activity ratio, the ratio of LH activity exhibited by serum pools 1-5 in the in vitro bioassay relative to that yielded by the immunoassay, calculated after conversion of the results to milliinternational units per mL 2nd IRP-HMG. 
Deconvolution analysis of GnRH-induced LH pulses
Deconvolution analysis was applied to compute the amplitude and mass of significant LH secretory bursts as well as to estimate the apparent endogenous LH half-life (t 1/2 ) in blood sampled at 10-min intervals after the administration of each of the two consecutive pulses of exogenous low and high dose GnRH (28, 29) . Each LH pulse was fit independently to allow for possible differences in the mode of LH secretion to the two doses of exogenous GnRH. Based on equivalent secretory burst half-durations and half-lives at the two GnRH doses, the optimized estimates of these parameters were determined from both pulse episodes considered jointly for statistical purposes (30, 31) . The mass of each GnRH-stimulated LH secretory burst is the analytical integral of the corresponding deconvolution-resolved secretory impulse.
Statistical analysis
Significant differences in mean serum E 2 , T, LH, and FSH concentrations; LH secretory measures (mass, amplitude, half duration, and apparent endogenous half-life of GnRH-stimulated LH secretory bursts) between obese and control subjects were determined by Bonferroni protected Student's unpaired two-tailed t test. Within-group differences in LH isoform distribution and LH B/I ratio before and after GnRH administration were determined by ANOVA followed by Student's paired t test. All values are reported as the mean Ϯ sem, unless specified. P Ͻ 0.05 was considered statistically significant.
Results

Baseline serum T, E 2 , and gonadotropin levels and secretory LH response to exogenous GnRH
Mean serum T and E 2 levels were significantly lower and higher, respectively, in the obese than in the control group [serum T, 13. In all subjects, a significant rise in serum LH levels was observed after administration of both low and high GnRH doses (Fig. 1) . Maximal LH concentrations occurred 10 -50 min (median, 20 min in both obese and control subjects) after the low GnRH pulse and between 10 -30 min (median, 30 and 20 min in obese and controls, respectively) after the high GnRH dose. In both groups, the burst mass of LH secreted was significantly higher after the 90-g GnRH dose (obese group, 43.8 Ϯ 9.0 vs. 61.5 Ϯ 11.5 IU/L; control group, 31.6 Ϯ 3.8 vs. 49.2 Ϯ 10.2 IU/L for the low and high GnRH doses, respectively; P ϭ 0.01 for both groups). Although the mean magnitude of LH response to both GnRH doses was higher in the obese subjects than in the control group (see above), the differences did not reach statistical significance. Likewise, there were no differences between the obese and control subjects in the magnitude of LH secretory amplitude (12.7 Ϯ 5.16 vs. 7.4 Ϯ 2.45 IU/L⅐min) and half-duration (6.4 Ϯ 2.0 vs. 6.7 Ϯ 1.1 min) of the GnRH-provoked LH bursts. The apparent endogenous LH half-lives of the deconvolved GnRH-induced LH pulses were significantly (P Ͻ 0.05) shorter in the obese group (98 Ϯ 11 min) than in controls (132 Ϯ 10 min).
Distribution of serum LH isoforms
Chromatofocusing disclosed consistent LH immunoactivity within a pH range of 4.0 -9.9 as well as in those fractions recovered after the addition of 1.0 mol/L NaCl to the chromatofocusing columns. In both groups, serum LH isoforms present in basal conditions were predominantly recovered at pH values of 6.99 or less (Fig. 3) . The percentage of LH immunoactivity recovered in basic pH values (pH Ն7.0) was significantly (P Ͻ 0.05) higher in obese than in control individuals. This increase in basic LH isoforms mainly occurred at the expense of the more basic isotypes recovered within the pH range of 8.0 -8.9 (not shown). In both groups, administration of 10 and 90 g GnRH, provoked a significant increase in the secretion of basic LH isoforms. Although the relative abundance of more basic isoforms released in response to both GnRH challenges was higher in the obese than in the control group, the difference reached statistical significance only for those isoforms secreted in response to the high dose (Fig. 3) . The proportion of basic LH isoforms released in response to the high GnRH dose also exceeded that of their acidic (pH Յ6.99) counterparts in the overweight individuals, but not in the nonobese control subjects (Fig. 3,  lower panel) .
In vitro B/I ratio of serum LH
Five serum LH pools from each subject were tested at two or three dose levels for LH bioactivity employing the homologous in vitro bioassay system. Incubation of HEK-293 cells expressing the recombinant human LH receptor with increasing amounts of LER-907 or the serum pools from each set of samples induced significant and parallel dose-dependent cAMP accumulation (Fig. 4) . In two subjects from each group, baseline levels of in vitro bioactive LH present in pool 1 were undetectable by the bioassay, whereas in four obese and the remaining controls only the largest serum aliquot (50 L) showed measurable LH bioactivity. The baseline B/I LH ratios were 0.30 Ϯ 0.1 and 0.35 Ϯ 0.1 for obese and control subjects, respectively (P ϭ NS). The B/I LH ratios for all other serum pools are shown in Table 1 . Ratios of B/I LH present in pools 2 and 3 (collected from samples obtained 10 -120 min and 130 -240 min after low dose GnRH administration, respectively; see Fig. 1 ) were similar in obese and controls. However, LH released by obese subjects in response to the high GnRH dose exhibited significantly lower ratios than those detected in normal individuals. In both groups, LH present in pools 3 and 5 (last 2 h after the low and high dose GnRH challenges) exhibited lower B/I ratios than molecules released immediately (first 2 h) after GnRH administration. The lowest B/I LH ratios were detected in pool 5 from the obese subjects (Table 1) .
Discussion
The present study reveals that circulating LH in obese individuals contains an increased proportion of more basic isoforms compared with that in men with normal BMI. This distinction in LH species between normal and obese subjects was not significantly modified by exogenous GnRH administration, which also allowed analysis of isoforms presumptively present in distinct intracellular pools in gonadotrope cells (19 -21) . Several mechanisms may explain this shift toward more basic LH isoforms in obese men. Some in vitro and in vivo studies indicate that GnRH may regulate posttranslational LH glycosylation (14, 15, 20, 21, 32) . According to this reasoning, in obese subjects the higher proportion of basic isoforms may result from increased exposure to endogenous GnRH subserved by the reduced serum T levels (33, 34) . Our study strategy, however, did not allow us to clearly recognize any significant alteration in LH release in either basal or GnRH-stimulated conditions in obese subjects, which contrasts with those observed in normal women during the late follicular phase and in patients with polycystic ovarian syndrome, in whom an association between the secretion of more basic LH isoforms and accentuated signaling of and/or heightened pituitary responsiveness to GnRH (presumptively facilitated by an enhanced estrogen milieu) has been observed (22, 24, 35, 36) . Alternatively, elevated proportions of more basic LH isoforms in obese men may be due solely to increased pituitary exposure to endogenous estrogens. Evidence derived from clinical and experimental studies supports this possibility. Serum LH from postmenopausal women, which is more negatively charged than at any stage of the menstrual cycle (36) , becomes less acidic during longterm estrogen treatment (37, 38) . In castrated female rats, sulfation and N-acetylgalactosamine incorporation into the oligosaccharides of LH is significantly reduced by estrogen treatment (18) . More recently, we have shown that messenger ribonucleic acid expression of anterior pituitary ␣-2,3-sialyltransferase [one of the enzymes that incorporate sialic acid residues into the protein core of glycoprotein hormones (39) ] is negatively regulated by estrogens (40) . Finally, reduced serum T levels may also account for the increased production of basic LH isoforms by gonadotropes in obese men. In wethers, dihydrotestosterone administration increased the percentage of less basic intrapituitary LH isoforms (41) , and in humans, serum T levels correlate with more acid LH isotypes in the circulation (42) . Based on the foregoing considerations, we suggest that the sustained gonadotrope exposure to an altered sex steroid hormone milieu, marked by a relatively increased serum E 2 /T ratio, promotes the elevated production of basic isoforms in overweight individuals.
Although in the relatively small cohort of obese subjects studied we found normal integrated baseline serum LH concentrations and marginally increased exogenous GnRHprovoked LH secretory parameters, one frequent sampling study detected a state of relative hypogonadotropic hypogonadism in morbid obesity (5) . This study, however, analyzed a group of obese subjects who were older and exhibited a higher degree of obesity than the population studied here. Thus, the degree of alteration of the hypothalamic-pituitary unit in obesity may be determined by multiple factors, including the subject's age, magnitude, and duration of obesity and even the degree of hypothalamic resistance to leptin, a protein recently implicated in the neuroendocrine regulation of the reproductive axis in rodents of both sexes (43) .
There is compelling evidence that the oligosaccharide structures on glycoprotein hormones influence their plasma half-lives and consequently the in vivo bioactivity of the hormone (13, 44 -50) . Recent studies have shown that within the large array of human LH isoforms, the more basic variants exhibit the lowest sialic acid content and that enzymatic desialylation of the more acidic isoforms decreases the plasma half-life of the hormone (48, 50) . In the present study the estimated half-time of endogenous LH disappearance from plasma in the control subjects (2.2 h) was similar to that previously calculated employing the same deconvolution analysis of exogenous GnRH-stimulated LH bursts in normal individuals (ϳ1.9 h) (51, 52) or recombinant human LH infused in leuprolide-suppressed middle-aged men (53) . In the obese group, however, the calculated plasma half-life of the LH isoform mixture released in response to exogenous GnRH was significantly lower (1.6 h). Further, the decrease in the plasma half-life of endogenous LH in obese individuals correlated with the presence of an increased proportion of more basic/less sialylated LH isoforms in circulation, an association consistent with the presence of altered posttranslational processing of LH molecules in obesity. The ultimate outcome of a reduced circulatory survival in the gonadotropic signal would be a decrease in the in vivo bioactivity of the hormone. The extent to which this contributes to the decreased T levels exhibited by obese men is not known (1) (2) (3) (4) (5) . As testicular responsiveness to exogenous hCG in obesity is normal (1, 9) , factors other than Leydig cell dysfunction probably contribute to the varying degree of hypogonadism prevailing in severe obesity. The in vitro B/I ratio of LH isoforms isolated from human pituitaries, as quantitated by steroidogenic bioassays, is lowest in the more acidic isoforms [isoelectric points (pI) 6.0 -7.0], gradually increases with less acidic isoforms, reaches its plateau in isoforms with pI values of approximately 7.2-8.0, and then decreases in the more basic (pI Ͼ8.0) variants (20, 50) . This bell-shaped profile of the in vitro bioactivity of LH isoforms is similar to that reported for the pituitary FSH charge isoforms in which absent bioactivity in aromatization assays, yet detectable FSH-like immunoreactivity, has been detected in variants recovered at high basic pH values, which represent presumptively underglycosylated variants (54, 55) . In the present study we employed a homologous in vitro LH bioassay system to assess the biological potency of the isoform mixture released from the pituitary in response to endogenous (basal) and exogenous GnRH. Both normal and obese subjects manifested a significant increase in the B/I ratio of LH secreted immediately after exogenous iv administration of a low (10-g) GnRH dose (a dose sufficient to release LH from an intracellular, biologically enriched, releasable pool). An increase in the B/I LH ratio in a homologous LH bioassay is in agreement with previous data showing that exogenous low dose iv GnRH administration results in preferential release of bioactive LH in a rat Leydig cell bioassay, with a consequent increase in the plasma B/I LH ratio in normal men (21) . Further, in samples collected during the third and fourth hours after the low dose GnRH challenge, the serum B/I ratio declined concomitantly with the reestablishment of endogenously GnRH-controlled LH secretion. More vividly, administration of a supraphysiological dose of GnRH (90 g) unmasked an intrinsic abnormality in the capability of the pituitary gland in obese men to synthesize bioactive LH, as disclosed by the reduced LH B/I ratio in delayed pools 4 and 5. Putative gonadotroph failure to synthesize highly bioactive LH may represent an additional mechanism for the hypogonadal state inferred in morbid obesity.
The present study does not unambiguously identify whether the abnormality in the capability of the pituitary gland to synthesize highly bioactive LH in obese men under highly demanding conditions (such as that imposed by pharmacological doses of exogenous GnRH) is due to the decreased serum T levels and/or the sustained gonadotrope exposure to moderately elevated serum estrogens or other nonsteroidal factors. Although some in vitro studies in rodents have shown that exposure to T increases the B/I ratio of LH secreted by gonadotrophs (56) , other evidence derived from in vivo studies demonstrates that sustained endogenous hyperestrogenism is associated with the suppression of plasma concentrations of biologically active LH in man (57) . The latter would be in line with the concept that estrogens decrease the sialylation of LH and FSH, thus producing incompletely glycosylated and more basic molecules (18, 40) , some of which may exhibit decreased in vivo biological potency and half-lives (20, 50, 54, 55).
In summary, the charge distribution of circulating LH isoforms is altered in severe obesity, such that an increased proportion of more basic isoforms is secreted under both endogenous and exogenous GnRH-stimulated conditions. This shift toward more basic isoforms in obesity appears to alter the survival time of this gonadotropin in the circulation and its potential to elicit a biological response at the human LH receptor level as well. These alterations in LH structure and function might be subserved by reduced serum T and/or a sustained rise in endogenous estrogens in obesity. Whatever the cause, abnormalities in the regulatory mechanisms that control both the circulating residence time and the intensity of the LH signal may contribute in part to the hypogonadic state observed in severe obesity in males.
